ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Epigenome-wide association study of cerebrospinal fluid-based biomarkers of Alzheimer's disease in cognitively normal individuals.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Differential DNA methylation in blood as potential mediator of the association between ambient PMMolecular psychiatry · 2026Article
- Diagnostic and Prognostic Value of Epigenetic Markers in Neurological Diseases. A Narrative Review.Cellular and molecular neurobiology · 2026Review
- Epigenetic aging and rejuvenation of the brain: drivers, consequences, and interventions.BMB reports · 2026Review
- Epigenome-wide association study of cerebrospinal fluid-based biomarkers of Alzheimer's disease in cognitively normal individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
introductionCerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) are reliable predictors of future AD risk. We investigated whether pre-clinical changes in AD CSF biomarkers are reflected in blood DNA methylation (DNAm) levels in cognitively normal participants.
methodsWe profiled blood-based DNAm with the EPIC array in participants without a diagnosis of cognitive impairment in the Emory Healthy Brain Study (EHBS; N = 495), Alzheimer's Disease Neuroimaging Initiative (N = 122), and Parkinson's Progression Markers Initiative (N = 118) cohorts. Their CSF amyloid beta 42, total tau (t-tau), and phosphorylated tau181 levels were quantified using Elecsys immunoassays. We conducted epigenome-wide association studies to assess associations between DNAm and CSF biomarkers of AD.
resultsIn EHBS, no loci were Bonferroni significant after adjusting for confounding factors. In the meta-analysis of all three cohorts, DNAm in cg22976567 (LMNA) was significantly associated with higher CSF t-tau levels. DISCUSSION: Our study showed little evidence of an association between differential blood-based DNAm and pre-clinical AD CSF biomarkers. HIGHLIGHTS: We conducted one of the largest (n = 735) blood DNA methylation (DNAm) studies of Alzheimer's disease cerebrospinal fluid (AD CSF) biomarkers. This is the first epigenome-wide association study in cognitively normal participants examining AD CSF biomarkers. Limited associations between blood DNAm and AD CSF biomarkers were identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.